Executive Board

President

David Schultz – Co-Founder & Ryan’s Dad

 

Vice President

Maria Schultz – Co-Founder & Ryan’s Mom

 

Chairman of the Board

Jeannine Cimino – Berkshire Bank

 

Vice-Chairman of the Board

Matthew Candelori – Kramer Beverage
 

Secretary

Andrea Meier – AAA Mid-Atlantic

 

Treasurer

Linda Ialacci – Linda Ialacci CPA, LLC

 

Legal Counsel

Crivelli & Barbati – Hamilton NJ

Board of Directors

​Jessie Armstead – NY GIANTS & Hamilton Honda

Chris Cline – GEICO Hamilton

Justin Coecliff – Bank of America Merrill Lynch

Stacy Cucchiaro – Investors Bank

Tracey Destribats – Trenton Catholic Academy

Brian Klabbatz – Pennsylvania Steel Co., Inc.

Norman Koenigsberg - First Choice Loan Services 
Pat Locane – State of New Jersey

Kevin Manna – Jersey Mike's

Joseph Vasta - JET Electric Testing, LLC

Lisa Schaible  – Investors Bank

Nina Melker – Berkshire Bank

Denise Powers – Berkshire Bank
John Rossi – Arora & Associates, PC

Bill Rue Jr. – Rue Insurance

Michael A. Sabo – Pulse Media

Michael Saporito – Hamilton Honda

Andrew Sklarz – CURE Insurance Arena

Benny Tramo – Bloomberg LP

Cory Zeiter – Mixbin

Carlo Rago, PhD

Johns Hopkins

Dr. Rago received his PhD in Cellular and Molecular Medicine from the Johns Hopkins School of Medicine.  He was a recipient of the Ruth L. Kirschstein National Research Service Award, continuing his work in the Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins as a post-doctoral fellow in the Vogelstein lab.  He co-authored over 30 papers in high-profile journals and helped co-develop a comprehensive genetic test for Duchenne muscular dystrophy.  He has also participated in discussions at the Food and Drug Administration (FDA) to help develop a framework to understand patient perspectives and help define "permissible risk" for clinical trial regulatory decisions.  He also formally lobbied the FDA to include DMD in PDUFA-V.

 

Dr. Rago was the recipient of the Ryan's Quest HERO award in 2012 and has been invited to speak around the world to promote transparency, collaboration, and biomedical progress.